Change of Registered Address

Summary by AI BETAClose X

Thalia Therapeutics plc has announced an immediate change to its registered address to 2 Portman Street, London, W1H 6DU. The company, which is developing its proprietary gene delivery system Nuvec® for advanced therapies, made this announcement on April 20, 2026. This administrative update is the sole focus of the RNS release and does not contain any financial performance data or strategic operational changes that would directly impact the stock share price.

Disclaimer*

Thalia Therapeutics PLC
20 April 2026
 

 

 

 

 

20 April 2026

 

Thalia Therapeutics plc

 

("Thalia" or the "Company")

 

Change of Registered Address

 

Thalia Therapeutics plc (AIM: THAT), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it has changed its registered address to 2 Portman Street, London, W1H 6DU with immediate effect.

 

- Ends -

 

For more information please contact:

 

Thalia Therapeutics plc

Dr David H Solomon, Chief Executive Officer

 

Via Thalia Investor Hub

https://investors.thaliatx.com/link/y5RKGe

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Matthew Johnson/Jen Clarke (Corporate Finance)

Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44 (0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker

Andy Thacker

Guy McDougall 

Tel: +44 (0)20 3657 0050

Northstar Communications Limited

Investor Relations

Sarah Hollins

Tel: +44 (0)20 7183 2463

 

 

About Thalia Therapeutics plc

 

Thalia Therapeutics plc is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.

 

RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. Thalia Therapeutics is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets. 

 

Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to enable oral delivery, avoidance of unwanted immune responses, and excellent stability and storage. 

 

For further information visit www.thaliatx.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Thalia Therapeutics plc (THAT)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today